Drugs / HR091506
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07076459 | Jul → Aug 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05347498 | Apr → Jul 2022 | gout | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06414837 | Jun 2024 → Jun 2026 | gout | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT06139393 | Dec 2023 → Aug 2025 | gout | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HR091506 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05347498 ↗ |
| Route | Oral | “subjects received oral administration” NCT07076459 ↗ |